Amygdaloid administration of tetrapentylammonium attenuates development of pain and anxiety-like behavior following peripheral nerve injury | Zendy

Zuyue Chen | Zendy; Hong Wei | Zendy; Boriss Sagalajev | Zendy; Ari Koivisto | Zendy; Antti Pertovaara | Zendy

Open Access

Amygdaloid administration of tetrapentylammonium attenuates development of pain and anxiety-like behavior following peripheral nerve injury

Author(s) -

Zuyue Chen,

Hong Wei,

Boriss Sagalajev,

Ari Koivisto,

Antti Pertovaara

Publication year - 2018

Publication title -

pharmacological reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.706

H-Index - 83

eISSN - 2299-5684

pISSN - 1734-1140

DOI - 10.1016/j.pharep.2018.08.005

Subject(s) - neuropathic pain , medicine , sni , anesthesia , nerve injury , perioperative , chronic pain , minocycline , allodynia , pharmacology , hyperalgesia , nociception , receptor , physical therapy , biochemistry , chemistry , microbiology and biotechnology , hydrolysis , acid hydrolysis , biology , antibiotics

The central amygdaloid nucleus (CeA) is involved in processing and descending regulation of pain. Amygdaloid mechanisms underlying pain processing and control are poorly known. Here we tested the hypothesis that perioperative CeA administration of tetrapentylammonium (TPA), a non-selective THIK-1 channel blocker and thereby inhibitor of microglia, attenuates development of chronic neuropathic pain and comorbid anxiety-like behavior.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research